Table 1 Patient populations and baseline characteristics
Characteristic | Maintenance (n = 18) | Treatment (n = 33) | Total (n = 51) |
|---|---|---|---|
Age, years | 65.5 (44–86) | 63 (36–86) | 63 (36–86) |
Diagnosis | |||
Epithelial ovarian cancer | 17 (94%) | 30 (91%) | 47 (92%) |
Fallopian tube or primary peritoneal cancer | 1 (6%) | 3 (9%) | 4 (8%) |
Histology | |||
Serous | 18 (100%) | 31 (94%) | 49 (96%) |
Other* | 0 | 2 (6%) | 2 (4%) |
FIGO stage | |||
I/II | 2 (11%) | 2 (6%) | 4 (8%) |
III | 15 (83%) | 25 (76%) | 40 (78%) |
IV | 1 (6%) | 5 (15%) | 6 (12%) |
Unknown | 0 | 1 (3%) | 1 (2%) |
ECOG PS | |||
0 | 7 (39%) | 12 (36%) | 19 (37%) |
1 | 10 (56%) | 15 (45%) | 25 (49%) |
2 | 0 | 3 (9%) | 3 (6%) |
Unknown | 1 (6%) | 3 (9%) | 4 (8%) |
BRCA status | |||
BRCA mutant | 3 (17%) | 28 (85%) | 31 (61%) |
Germline† | 2 (11%) | 21 (64%) | 23 (45%) |
Somatic† | 1 (6%) | 8 (24%) | 9 (18%) |
BRCA wildtype | 13 (72%) | 3 (9%) | 16 (31%) |
Unknown | 2 (11%) | 2 (6%) | 4 (8%) |
Mutation in other HRR genes | |||
RAD51C | 1 (6%) | 1 (3%) | 2 (4%) |
Primary cytoreductive surgery | |||
PDS | 12 (67%) | 23 (70%) | 35 (69%) |
IDS | 5 (28%) | 10 (30%) | 15 (29%) |
No surgery | 1 (6%) | 0 | 1 (2%) |
Primary surgery outcome ‡ | |||
R0 | 9 (53%) | 22 (67%) | 31 (62%) |
R1 | 8 (47%) | 9 (27%) | 17 (34%) |
Unknown | 0 | 2 (6%) | 2 (4%) |
Salvage surgery | |||
Yes | 6 (35%) | 6 (18%) | 12 (24%) |
No | 11 (65%) | 27 (82%) | 38 (76%) |
Number of previous treatment lines | 3 (1–6) | 5 (1–9) | 4 (1–9) |
1 | 2 (11%) | 2 (6%) | 4 (8%) |
2 | 5 (28%) | 3 (9%) | 8 (16%) |
3 | 6 (33%) | 5 (15%) | 11 (22%) |
4 | 2 (11%) | 5 (15%) | 7 (14%) |
≥ 5 | 3 (17%) | 18 (55%) | 21 (41%) |
Previous bevacizumab use | 10 (56%) | 17 (52%) | 27 (53%) |
Prior PARPi | 1 (6%) | 13 (39%) | 14 (27%) |
Platinum status | |||
Platinum resistant | NA | 26 (79%) | 26 (51%) |
Platinum sensitive | 18 (100%) | 7 (21%) | 25 (49%) |
Measurable disease (investigator assessed) | |||
Yes | 9 (50%) | 28 (85%) | 37 (73%) |
No | 9 (50%) | 5 (15%) | 14 (27%) |
Unknown | 0 | 0 | 0 |
Response to last platinum (RECIST) | |||
CR | 6 (33%) | NA | NA |
PR | 10 (56%) | NA | NA |
SD | 2 (11%) | NA | NA |
Comorbidities § | |||
Hypertension | 4 (22%) | 6 (18%) | 10 (20%) |
Diabetes mellitus | 2 (11%) | 1 (3%) | 3 (6%) |
Obesity | 2 (11%) | 0 | 2 (4%) |
Hypothyroidism | 0 | 2 (6%) | 2 (4%) |